Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program

M A Pfaller; D J Diekema; A L Colombo; C Kibbler; K P Ng; D L Gibbs; V A Newell; Global Antifungal Surveillance Group

doi:10.1128/JCM.00863-06

Back

Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program

Journal article

Open access

Peer reviewed

Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program

M A Pfaller, D J Diekema, A L Colombo, C Kibbler, K P Ng, D L Gibbs, V A Newell and Global Antifungal Surveillance Group

Journal of clinical microbiology, Vol.44(10), pp.3578-3582

10/2006

DOI: 10.1128/JCM.00863-06

PMCID: PMC1594768

PMID: 17021085

Files and links (1)

url

https://doi.org/10.1128/JCM.00863-06View

Published (Version of record) Open Access

Abstract

Candida rugosa is a fungus that appears to be emerging as a cause of infection in some geographic regions. We utilized the extensive database of the ARTEMIS DISK Antifungal Surveillance Program to describe the geographic and temporal trends in the isolation of C. rugosa from clinical specimens and the in vitro susceptibilities of 452 isolates to fluconazole and voriconazole. C. rugosa accounted for 0.4% of 134,715 isolates of Candida, and the frequency of isolation increased from 0.03% to 0.4% over the 6.5-year study period (1997 to 2003). C. rugosa was most common in the Latin American region (2.7% versus 0.1 to 0.4%). Decreased susceptibility to fluconazole (40.5% susceptible) was observed in all geographic regions; however, isolates from Europe and North America were much more susceptible (97 to 100%) to voriconazole than those from other geographic regions (55.8 to 58.8%). C. rugosa was most often isolated from blood and urine in patients hospitalized at the Medical and Surgical inpatient services. Notably, bloodstream isolates were the least susceptible to both fluconazole and voriconazole. C. rugosa should be considered, along with the established pathogens Candida krusei and Candida glabrata, as a species of Candida with reduced susceptibility to the azole antifungal agents.

Global Health

Antifungal Agents - pharmacology

Triazoles - pharmacology

Candida - classification

Fluconazole - pharmacology

Humans

Voriconazole

Candida - drug effects

Pyrimidines - pharmacology

Candidiasis - microbiology

Drug Resistance, Fungal

Population Surveillance

Details

Title: Subtitle: Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program
Creators: M A Pfaller - Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242, USA. michael-pfaller@uiowa.edu
D J Diekema
A L Colombo
C Kibbler
K P Ng
D L Gibbs
V A Newell
Global Antifungal Surveillance Group (Author)
Resource Type: Journal article
Publication Details: Journal of clinical microbiology, Vol.44(10), pp.3578-3582
DOI: 10.1128/JCM.00863-06
PMID: 17021085
PMCID: PMC1594768
NLM abbreviation: J Clin Microbiol
ISSN: 0095-1137
eISSN: 1098-660X
Publisher: United States
Language: English
Date published: 10/2006
Academic Unit: Infectious Diseases; Epidemiology; Pathology; Internal Medicine
Record Identifier: 9983986263502771

Metrics

27 Record Views

74 Times Cited - Web of Science